Chael Sonnen Fails Second Drug Test Administered By NSAC

Chael Sonnen

The aftermath of TRT strikes again.

Former two-time UFC middleweight title contender tested positive yet again for banned substances earlier this month in a second random drug test administered by the ().

Sonnen, who announced his retirement from MMA recently, was asked by the NSAC to take an additional blood and urine test on June 5th in Portland, Oregon, because at that time he was still officially scheduled to fight at in Las Vegas.

The NSAC learned earlier this week that “The American Gangster” had failed those drug tests, as he tested positive for human growth horomone (HGH), recombinant human erythropoietin, anastrozole and human chorionic gonadotropin.

Update: UFC Issues A Statement Regarding Chael Sonnen’s Latest Failed Drug Test

At the time of Sonnen’s second drug test, the results of his previous tests, which took place on May 24th, had not been released. Those test results were released on June 10th, when it became known that he had tested positive for anastrozole, a non-steroidal aromatase-inhibiting drug used to treat breast cancer, and clomiphene, which is used to treat female infertility.

Both Sonnen and the UFC became aware of the news of his second drug test failure earlier this week by the NSAC.

Following the failed drug test result, Sonnen offered the following reaction to MMAFighting.com:

“Yes, the Commission is aware of other prescribed medications I was taking and I will not challenge their allegations. I will cooperate with the Commission and look forward to having a dialogue about how fighters who transition off TRT can avoid violating any rules.”

According to NSAC chairman , Sonnen’s case has now been amended to include the second drug test failure, which will be on the NSAC’s next meeting agenda on July 23rd in Las Vegas.

What is your reaction to Chael Sonnen failing another drug test? Talk about it in our official FACEBOOK page, or on our official TWITTER page. You can also talk about it in our popular FORUMS.